Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
Kasey J Leger, Nora Robison, Hari K Narayan...
https://pubmed.ncbi.nlm.nih.gov/38107263/Actively Recruiting
Led by Children's Oncology Group · Updated on 2026-09-17
1400
Participants Needed
206
Research Sites
N/A
Total Duration
Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.
CONDITIONS
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CPX-351 and/or Gilteritinib-Enhanced Therapy | Standard Chemotherapy |
|---|---|---|
| What is it? | Combination therapies that include CPX-351 (liposome-encapsulated daunorubicin-cytarabine) instead of conventional daunorubicin and cytarabine, with gilteritinib added for participants with FLT3 mutations, alongside other chemotherapy drugs. | Intensive chemotherapy using standard drugs such as daunorubicin, cytarabine, etoposide, and other agents, administered according to pediatric AML protocols. |
| Role in trial | Investigational treatment: evaluating the impact of CPX-351 and, when relevant, gilteritinib on survival and relapse in newly diagnosed pediatric AML. | Comparator arm: reflects current pediatric AML chemotherapy, serving as the benchmark for investigational regimens. |
| Primary use | Intended as first-line therapy for children and young adults newly diagnosed with AML, including those with FLT3 mutations. | Current standard first-line chemotherapy for newly diagnosed pediatric AML, regardless of FLT3 mutation status. |
| How is it given or performed? | CPX-351 is given by intravenous infusion; gilteritinib is taken by mouth or feeding tube in patients with FLT3 mutations; additional chemotherapy drugs are administered as infusions or injections based on the protocol. | Daunorubicin and cytarabine are given as intravenous infusions; additional agents such as etoposide, gemtuzumab ozogamicin, and methotrexate are administered intravenously or intrathecally according to pediatric AML protocols. |
| Evidence maturity | Efficacy and safety in newly diagnosed pediatric AML are still being actively investigated; phase III randomized results are not yet available. | Multiple clinical studies have established standard chemotherapy’s efficacy, forming the current benchmark for pediatric AML outcomes. |
| Important limitations | Data on long-term outcomes and late effects for CPX-351 and gilteritinib in pediatric AML are limited; potential risks such as cardiotoxicity, infection, and unknown rare side effects require further study. | Conventional chemotherapy is associated with significant toxicities, including risk of infections, organ dysfunction, and relapse, particularly in high-risk patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 10 to 31 days
Participants receive initial chemotherapy treatments including drugs like cytarabine, daunorubicin, dexrazoxane, gemtuzumab ozogamicin, and intrathecal therapies based on risk group and FLT3 status.
Multiple visits during treatment days
Duration - Approximately 8 to 31 days
Participants continue chemotherapy with similar drugs and intrathecal treatments, with gilteritinib added for some patients with FLT3 mutations.
Multiple visits during treatment days
Duration - Several weeks over multiple cycles
Participants receive intensified chemotherapy including high-dose cytarabine, etoposide, mitoxantrone, asparaginase, and ongoing intrathecal therapies, with gilteritinib for eligible patients.
Multiple visits during treatment days
Duration - Varies per patient, up to 1 year for maintenance
Eligible patients undergo allogeneic HSCT after intensification and receive maintenance therapy with gilteritinib for up to one year post-transplant.
Visits for transplant and regular follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
14
Have more questions? Get in touch with our team for quick support
Kasey J Leger, Nora Robison, Hari K Narayan...
https://pubmed.ncbi.nlm.nih.gov/38107263/Kasey J Leger, Michael J Absalon, Biniyam G Demissei...
https://pubmed.ncbi.nlm.nih.gov/38947228/Jeffrey R Andolina, Carol Fries, Renee Boulware...
https://pubmed.ncbi.nlm.nih.gov/33843815/Jessica A Pollard, Todd A Alonzo, Robert B Gerbing...
https://pubmed.ncbi.nlm.nih.gov/42497367/Children's Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor